Can you get high on Lomotil?
By
Dr Milena Locci de Oliveira (PhD)
Author bio
Dr Milena Locci de Oliveira is a Pharmacist and Doctor of Philosophy in Sciences from the University of São Paulo (USP). She has experience in microbiology, analytical toxicology, and clinical pharmacokinetics. She writes and reviews content on these topics.
Dr Milena’s Highlights:
-PhD in Sciences, University of São Paulo, Brazil, 2019.
-University College London (UCL) – Semester of remote collaboration in the areas of Pharmacometrics and Population Pharmacokinetics, 2018.
-Bachelor in Biochemical Pharmacy, University of São Paulo, Brazil, 2013.
“Science can be translated, and it is essential that everyone has access to quality information to make informed decisions” – Dr Milena Oliveira, PhD.
Professional Experience:
With a decade-long career as a researcher, Dr Milena has amassed extensive experience in conducting research projects in microbiology, analytical toxicology, and clinical pharmacokinetics.
Her expertise also extends to the preparation of technical and scientific reports, literature reviews, data analysis, and scientific communication, both oral and written.
Dr Milena has served as a Clinical Pharmacist, providing expert supervision and guidance to teams during the challenging times of the COVID-19 pandemic, particularly in the ICUs of two reference hospitals for patient hospitalization.
In her most recent role, Dr Milena worked on the implementation of the deliberatives of the São Paulo State Government Pharmaceutical Assistance Coordination. These decisions were aimed at ensuring medication access within the Unified Health System.
A widely multidisciplinary background enabled Dr Milena to become a professional capable of integrating scientific knowledge into private initiatives, education, and healthcare, delivering consistent services in patient safety and population health.
Professional Memberships & Affiliations:
Dr Milena Oliveira is a member of the Regional Council of Pharmacy of the State of São Paulo, Brazil.
Education:
-PhD in Sciences, University of São Paulo, Brazil, 2019.
-University College London (UCL) – Semester of remote collaboration, 2018.
-Bachelor in Biochemical Pharmacy, University of São Paulo, Brazil, 2013.
Relevant Published Work & Citations:
Oliveira ML de, Rocha A, Nardotto GHB, Pippa LF, Simões BP, Lanchote VL. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia. Journal of Pharmaceutical and Biomedical Analysis. Nov 2020. 191:113-124.
Abstracts. CPT: Pharmacometrics & Systems Pharmacology. 2020 Nov; 9 (S1).
Pippa LF, Oliveira ML de, Rocha A, de Andrade JM, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis. 2020 Jun 5; 185:113-231.
Godoy ALPC, De Jesus C, De Oliveira ML, Rocha A, Pereira MPM, Larangeira DF, Lanchote VL, Barrouin-Melo SM. Determination of Allopurinol and Oxypurinol in Dogs Plasma by High-Performance Liquid Chromatography with an Ultraviolet Detector: Application for Pharmacokinetic Studies. J Chromatogr Sep Tech. 2017; 8 (4).
Clímaco EC, Oliveira ML de, Pitondo-Silva A, Oliveira MG, Medeiros M, Lincopan N, et al. Clonal complexes 104, 109 and 113 playing a major role in the dissemination of OXA-carbapenemase-producing Acinetobacter baumannii in Southeast Brazil. Infection, Genetics and Evolution. 2013 Oct;19:127–33.
Conference Papers:
Oliveira, M. L.; NARDOTTO, G. H. B.; PIPPA, L. F.; ROCHA, A.; SIMOES, B. P.; LANCHOTE, V. L. . Daunorubicin metabolism and urinary excretion in patients with acute myeloid leukemia. In: 84th Annual Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT) and the 20th Annual Meeting of the Association of the Clinical Pharmacology Germany (VKliPha), 2018, Göttingen. Naunyn-Schmiedeberg’s Arch Pharmacol, 2018. v. 391. p. S76-S76.
Oliveira, M. L.; NARDOTTO, G. H. B. ; ROCHA, A. ; SIMOES, B. P. ; LANCHOTE, V. L. . The low contribution of urinary excretion in the elimination of daunorubicin and its metabolite daunorubicinol in patients with acute myeloid leukemia. In: 49th Brazilian Congress of Pharmacology and Experimental Therapeutics., 2017, Ribeirão Preto. Livro de Resumos, 2017. p. 64-64.
Oliveira, M. L.; PIPPA, L. F. ; ROCHA, A. ; SIMOES, B. P. ; LANCHOTE, V. L. . Quantification of daunorubicin and its metabolite daunorubicinol in human plasma by LC-MS/MS. In: I International Meeting of Environmental Health and Toxicology (IMEHTOX), 2016, Ribeirão Preto. Livro de Resumos, 2016.
Oliveira, M. L.; Clímaco, E.C. ; OLIVEIRA, M. G. ; Lincopan, N. ; Darini A.L.C. . PFGE typing of Carbapenem-Resistant Acinetobacter baumannii isolated from different University Hospitals. In: V International Postgraduate and Research Symposium, 2012.
Clímaco, E.C. ; SILVA, A. P. ; Oliveira, M. L. ; OLIVEIRA, M. G. ; Lincopan, N. ; Darini A.L.C. Relação clonal entre linhagens de Acinetobacter baumannii produtoras de carbapenemases da família OXA em quatro hospitais no Brasil. In: XXI Latin American Congress of Microbiology, 2012, Santos. XXI Latin American Congress of Microbiology, 2012.
Oliveira, M. L.; Clímaco, E.C. ; OLIVEIRA, M. G. ; Darini A.L.C. . Dissemintion of OXA carbapenemases genes in carbapenem-resistant Acinetobacter baumannii in University Hospital of Juiz de Fora, MG. In: 8th CIFARP – International Congress of Pharmaceutical Sciences, 2011, Ribeirão Preto.
Clímaco, E.C. ; Oliveira, M. L. ; OLIVEIRA, M. G. ; Darini A.L.C. . Avaliação do sequenciamento parcial do gene rpoB e de seus flanqueadores para identificação de espécies de Acinetobacter na rotina laroratorial. In: 2° International Symposium on Clinical Microbiology, 2010, Florianópolis.
You can view some of Dr Milena’s work below and links to her professional profile.
Linkedin: https://www.linkedin.com/in/dra-milena-locci-de-oliveira-28986042/?locale=en_US
ResearchGate: https://www.researchgate.net/profile/Milena-Oliveira-6
Escavador: https://www.escavador.com/sobre/5394254/milena-locci-de-oliveira
Lattes: https://buscatextual.cnpq.br/buscatextual/busca.do
Scopus: https://www.scopus.com/authid/detail.uri?authorId=57199779361
Scholar: https://scholar.google.com/citations?view_op=list_works&hl=pt-BR&user=1YUBDIQAAAAJ
Can you get high on Lomotil?
You can get high on Lomotil, but not on standard therapeutic doses. Lomotil contains Diphenoxylate, which is an opioid, meaning it can affect the brain and produce a sense of euphoria or relaxation when taken in high doses or in a way not prescribed by a doctor. (1,2)
When Lomotil is taken in excessive amounts or combined with other substances, it can lead to a range of euphoric effects. In some cases, the euphoria caused by high doses of Lomotil was found to be somewhat similar to Codeine.
It is important to note that using Lomotil in a manner not prescribed by a healthcare professional is unsafe and can have serious consequences. Misusing or abusing Lomotil can lead to dependence, addiction, and other health risks. (3,4)
If you have concerns about Lomotil use or are seeking to get high, it is important to reach out to a medical professional.
What are the signs of getting high from Lomotil?
If you have taken a high amount of Lomotil, you may experience the following signs and symptoms of getting high: (5)
- Euphoria
- Elevated or happy mood
- Calmness
- Relaxation
- Detachment from reality
- Disorientation
These signs and symptoms can vary in intensity and depend on the amount of medication you have taken. Some people may not even get to the high state and start to feel generally unwell.
How to cope with the effects of getting high from Lomotil?
If you are experiencing the effects of getting high from Lomotil and want to cope with them, there are a few things you can try. First, it’s important to remember that Lomotil is a medication that should be taken as directed by your healthcare provider.
If you have taken a high amount of the medication and feel unusual, you should immediately seek medical attention.
However, mild symptoms of getting high from Lomotil can be managed with the help of the following steps:
- Stay calm and relaxed: Remind yourself that the effects will wear off over time. Find a quiet and comfortable environment where you can rest and relax.
- Stay hydrated: Drink plenty of water or clear fluids to stay hydrated. This can help alleviate some discomfort and help your body flush out the medication.
- Avoid other substances: It’s important to avoid consuming any other substances, including alcohol or stimulants like Adderall or Vyvanse, as they can worsen the effects or interact with Lomotil in harmful ways.
- Follow up with your healthcare provider: If you have taken Lomotil inappropriately or are experiencing adverse effects, it’s crucial to consult with your doctor. They can provide appropriate guidance and help you manage any potential complications.
Was this helpful?
References
1.-
PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 13505, Diphenoxylate; [cited 2023 July 3]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Diphenoxylate
2.-
Jain M, Wylie WP. Diphenoxylate and Atropine. 2022 Nov 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 32644726. https://www.ncbi.nlm.nih.gov/books/NBK559300
3.-
Mehra A, Sarkar S, Basu D. Lomotil (diphenoxylate) dependence in India. Indian J Psychol Med. 2013 Jul;35(3):248-50. doi: 10.4103/0253-7176.119474. PMID: 24249925; PMCID: PMC3821200. https://pubmed.ncbi.nlm.nih.gov/24249925/
4.-
Joob B, Wiwanitkit V. Lomotil dependence. Indian J Psychol Med. 2014 Jul;36(3):348-9. doi: 10.4103/0253-7176.135401. PMID: 25035572; PMCID: PMC4100434. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100434/
5.-
McGuigan M, Lovejoy FH Jr. Overdose of Lomotil. Br Med J. 1978 Apr 15;1(6118):990. doi: 10.1136/bmj.1.6118.990-a. PMID: 638566; PMCID: PMC1603866. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1603866/
